Heteroaryl aminoguanidines and alkoxyguanidines and their...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 213/75 (2006.01) A61K 31/44 (2006.01) C07D 213/74 (2006.01) C07D 401/12 (2006.01) C07D 409/12 (2006.01) C07K 5/078 (2006.01)

Patent

CA 2311969

Aminoguanidine and alkoxyguanidine compounds are described, including compounds of Formula (VII), wherein X is O or NR9 and Het, R1, R7, R8, R12- R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

L'invention concerne des composés aminoguanidine et alcoxyguanidine, y compris des composés représentés par la formule (VII), dans laquelle X représente O ou NR?9¿, et Het, R?1¿, R?7¿, R?8¿, R?12¿-R?15¿, R?a¿, R?b¿, R?c¿, Z, et n sont spécifiés dans le descriptif, ainsi que leurs hydrates, leurs solvates ou leurs sels pharmaceutiquement acceptables, inhibant des enzymes protéolytiques telle que la thrombine. L'invention concerne également des méthodes de préparation de ces composés. Les composés de l'invention sont de potentiels inhibiteurs de protéases, en particulier les sérine protéases de type trypsine, tels que la chymotrypsine, la trypsine, la thrombine, la plasmine et le facteur Xa. Certains de ces composés présentent une activité antithrombotique à travers l'inhibition sélective et directe de thrombine. L'invention comprend une composition permettant d'inhiber la perte de plaquettes sanguines, la formation d'agrégations de plaquettes sanguines, la formation de fibrine, la formation de thrombus, et la formation d'un embole chez un mammifère, comprenant un composé de l'invention dans un excipient pharmaceutiquement acceptable. Les composés de l'invention peuvent également être utilisés en tant qu'anticoagulants incorporés dans des matières, ou physiquement liés à celles-ci, ces matières servant à la production de dispositifs utilisés pour les prélèvements sanguins, la circulation de sang et l'entreposage de sang, tels que cathéters, machines à hémodialyse, seringues et tubes pour prélèvements sanguins, tuyaux à sang et stents. En outre, ces composés peuvent être marqués de façon visible et utilisés pour l'imagerie in vivo de thrombi.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Heteroaryl aminoguanidines and alkoxyguanidines and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroaryl aminoguanidines and alkoxyguanidines and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl aminoguanidines and alkoxyguanidines and their... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1873189

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.